Edition:
United Kingdom

Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

6.41HKD
20 Feb 2019
Change (% chg)

HK$-0.13 (-1.99%)
Prev Close
HK$6.54
Open
HK$6.64
Day's High
HK$6.65
Day's Low
HK$6.21
Volume
110,559,682
Avg. Vol
69,847,861
52-wk High
HK$13.93
52-wk Low
HK$4.53

Latest Key Developments (Source: Significant Developments)

Sino Biopharmaceutical Says Anti-Tumor Drug Lenalidomide Capsule Gets Approval For Drug Registration
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANTI-TUMOR DRUG LENALIDOMIDE CAPSULE DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NMPA IN CHINA.  Full Article

Sino Biopharmaceutical Says Parecoxib Sodium For Injection Obtained Approval For Drug Registration
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::PARECOXIB SODIUM FOR INJECTION OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

Sino Biopharmaceutical Says Parecoxib Sodium For Injection Gets Approval For Drug Registration
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::SINO BIOPHARMACEUTICAL SAYS PARECOXIB SODIUM FOR INJECTION DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NMPA.  Full Article

Sino Biopharmaceutical Posts 9-Mth Revenue Of RMB15,730.16 Mln, Up 37.4 Pct
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::9-MONTH REVENUE RMB15,730.16 MILLION, UP 37.4 PERCENT.DECLARED PAYMENT OF A THIRD QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE.9-MONTH PROFIT ATTRIBUTABLE RMB2,201.26 MILLION, UP 22.0%.  Full Article

Sino Biopharmaceutical Says Unit's Product Obtains Approval For Drug Registration
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION OBTAINS APPROVAL FOR DRUG REGISTRATION.APPROVAL GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  Full Article

Sino Biopharmaceutical Says Trustee Further Purchased Shares Of Co For Total Consideration Of HK$48.6 Million
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::TRUSTEE FURTHER PURCHASED 6.5 MILLION SHARES OF CO FOR TOTAL CONSIDERATION OF HK$48.6 MILLION.  Full Article

Sino Biopharmaceutical Posts HY Profit Attributable Of RMB1,365.67 Mln
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::HY REVENUE RMB9,725.23 MILLION, UP 30.0%.H1 PROFIT ATTRIBUTABLE RMB1,365.67 MILLION 24.1% HIGHER.DECLARED PAYMENT OF A SECOND QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE.  Full Article

Sino Biopharmaceutical Announces Passing Of EU GMP Certification For Tenofovir Production Line
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANNOUNCES PASSING OF EU GMP CERTIFICATION FOR TENOFOVIR PRODUCTION LINE.  Full Article

Sino Biopharmaceutical Says Obtained Drug Registration Approval For Bortezomib
Friday, 20 Jul 2018 

July 20 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::BORTEZOMIB FOR INJECTION OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL DRUG ADMINISTRATION -PEOPLE'S REPUBLIC OF CHINA.  Full Article

Sino Biopharmaceutical Says Injection Obtained Drug Registration Approval By National Drug Administration
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::DOCETAXEL INJECTION HAS OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL DRUG ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  Full Article

China stocks jump on trade talk hopes, strong loan data

SHANGHAI, Feb 18 China stocks jumped on Monday after trade talks between the United States and Beijing saw progress ahead of a March 1 deadline, and new data showed Beijing's attempts to boost investment led to record new loans in January. ** At the midday break, the Shanghai Composite index was up 1.79 percent at 2,730.27 points. ** China's blue-chip CSI300 index was up 2.11 percent, with its financial sector sub-index higher by 2.01 percent. ** Chinese H-shares listed in Hong Kong